Tumors of the Mammary Gland

Withrow and MacEwen's Small Animal Clinical Oncology: Fifth Edition

Volumn , Issue , 2012, Pages 538-556

  Sorenmo, Karin U ^a   Worley, Deanna R ^b   Goldschmidt, Michael H ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c Department of Pathobiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901863871     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2362-5.00027-X     Document Type: Chapter

References (191)

1. Dorn CR, Taylor DO, Schneider R, et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968, 40:307-318.
2. Moe L Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl 2001, 57:439-443.
3. Egenvall A, Bonnett BN, Ohagen P, et al. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med 2005, 69:109-127.
4. Dobson JM, Samuel S, Milstein H, et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002, 43:240-246.
5. Bronden LB, Nielsen SS, Toft N, et al. Data from the Danish veterinary cancer registry on the occurrence and distribution of neoplasms in dogs in Denmark. Vet Rec 2010, 166:586-590.
6. Merlo DF, Rossi L, Pellegrino C, et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 2008, 22:976-984.
7. Benjamin SA, Lee AC, Saunders WJ Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 1999, 36:423-436.
8. Schneider R Comparison of age, sex, and incidence rates in human and canine breast cancer. Cancer 1970, 26:419-426.
9. Priester WA, Mantel N Occurrence of tumors in domestic animals: data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1971, 47:1333-1344.
10. Brodey RS, Goldschmidt MH, Roszel JR Canine mammary gland neoplasms. J Am Anim Hosp Assoc 1983, 19:61-90.
11. Kurzman ID, Gilbertson SR Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1986, 1:25-32.
12. Taylor GN, Shabestari L, Williams J, et al. Mammary neoplasia in a closed beagle colony. Cancer Res 1976, 36:2740-2743.
13. Sorenmo KU, Kristiansen VM, Cofone MA, et al. Canine mammary gland tumours: a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol 2009, 7:162-172.
14. Goldschmidt M, Shofer FS, Smelstoys JA Neoplastic lesions of the mammary gland. Pathobiology of the aging dog 2001, Iowa State University Press, Ames, Iowa. U. Mohr, W.W. Carlton, D.L. Dungworth (Eds.).
15. Rivera P, Melin M, Biagi T, et al. Mammary tumor development in dogs is associated with BRCA1 and BRCA2. Cancer Res 2009, 69:8770-8774.
16. Schneider R, Dorn CR, Taylor DO Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969, 43:1249-1261.
17. Sonnenschein EG, Glickman LT, Goldschmidt MH, et al. Body conformation, diet, and risk of breast cancer in pet dogs: a case-control study. Am J Epidemiol 1991, 133:694-703.
18. Misdorp W Canine mammary tumours: protective effect of late ovariectomy and stimulating effect of progestins. Vet Q 1988, 10:26-33.
19. Brodey RS, Fidler IJ, Howson AE The relationship of estrous irregularity, pseudopregnancy, and pregnancy to the development of canine mammary neoplasms. J Am Vet Med Assoc 1966, 149:1047-1049.
20. Stovring M, Moe L, Glattre E A population-based case-control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. APMIS 1997, 105:590-596.
21. Concannon PW, Spraker TR, Casey HW, et al. Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches. Fertil Steril 1981, 36:373-387.
22. Giles RC, Kwapien RP, Geil RG, et al. Mammary nodules in beagle dogs administered investigational oral contraceptive steroids. J Natl Cancer Inst 1978, 60:1351-1364.
23. Kwapien RP, Giles RC, Geil RG, et al. Malignant mammary tumors in beagle dogs dosed with investigational oral contraceptive steroids. J Natl Cancer Inst 1980, 65:137-144.
24. Selman PJ, van Garderen E, Mol JA, et al. Comparison of the histological changes in the dog after treatment with the progestins medroxyprogesterone acetate and proligestone. Vet Q 1995, 17:128-133.
25. Geil RG, Lamar JK FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey. J Toxicol Environ Health 1977, 3:179-193.
26. Yamagami T, Kobayashi T, Takahashi K, et al. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci 1996, 58:1079-1083.
27. Schafer KA, Kelly G, Schrader R, et al. A canine model of familial mammary gland neoplasia. Vet Pathol 1998, 35:168-177.
28. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
29. King MC, Marks JH, Mandell JB Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.
30. Easton DF, Ford D, Bishop DT Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271.
31. Fackenthal JD, Olopade OI Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007, 7:937-948.
32. Klopfleisch R, Gruber AD Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas. Vet Pathol 2009, 46:416-422.
33. Nieto A, Perez-Alenza MD, Del Castillo N, et al. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J Comp Pathol 2003, 128:260-268.
34. Perez Alenza D, Rutteman GR, Pena L, et al. Relation between habitual diet and canine mammary tumors in a case-control study. J Vet Intern Med 1998, 12:132-139.
35. Calle EE, Kaaks R Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
36. Carmichael AR, Bates T Obesity and breast cancer: a review of the literature. Breast 2004, 13:85-92.
37. Tymchuk CN, Tessler SB, Barnard RJ Changes in sex hormone-binding globulin, insulin, and serum lipids in postmenopausal women on a low-fat, high-fiber diet combined with exercise. Nutr Cancer 2000, 38:158-162.
38. Wu AH, Pike MC, Stram DO Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999, 91:529-534.
39. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998, 90:1292-1299.
40. Cleary MP, Grossmann ME Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 2009, 150:2537-2542.
41. Cleary MP, Grossmann ME, Ray A Effect of obesity on breast cancer development. Vet Pathol 2010, 47:202-213.
42. Rehm S, Stanislaus DJ, Williams AM Estrous cycle-dependent histology and review of sex steroid receptor expression in dog reproductive tissues and mammary gland and associated hormone levels. Birth Defects Res B Dev Reprod Toxicol 2007, 80:233-245.
43. Santos M, Marcos R, Faustino AM Histological study of canine mammary gland during the oestrous cycle. Reprod Domest Anim 2010, 45:e146-e154.
44. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17-35.
45. Russo J, Russo IH The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006, 102:89-96.
46. Okoh V, Deoraj A, Roy D Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 2011, 1815:115-133.
47. Dickson RB, Lippman ME, Slamon D UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer. Cancer Res 1990, 50:4446-4447.
48. Mol JA, Lantinga-van Leeuwen IS, van Garderen E, et al. Mammary growth hormone and tumorigenesis-lessons from the dog. Vet Q 1999, 21:111-115.
49. Selman PJ, Mol JA, Rutteman GR, et al. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 1994, 134:287-292.
50. van Garderen E, Schalken JA Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol 2002, 197:153-165.
51. Mol JA, Selman PJ, Sprang EP, et al. The role of progestins, insulin-like growth factor (IGF) and IGF-binding proteins in the normal and neoplastic mammary gland of the bitch: a review. J Reprod Fertil Suppl 1997, 51:339-344.
52. Hamelers IH, van Schaik RF, van Teeffelen HA, et al. Synergistic proliferative action of insulin-like growth factor I and 17 beta-estradiol in MCF-7S breast tumor cells. Exp Cell Res 2002, 273:107-117.
53. Thorne C, Lee AV Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Dis 2003, 17:105-114.
54. Laban C, Bustin SA, Jenkins PJ The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003, 14:28-34.
55. van der Burg B, Rutteman GR, Blankenstein MA, et al. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 1988, 134:101-108.
56. Osborne CK, Clemmons DR, Arteaga CL Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 1990, 37:805-809.
57. Dupont J, Le Roith D Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001, 54:149-154.
58. Queiroga FL, Perez-Alenza D, Silvan G, et al. Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci 2010, 89:396-403.
59. Queiroga FL, Perez-Alenza MD, Silvan G, et al. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17beta-estradiol) in canine mammary tumours. J Steroid Biochem Mol Biol 2008, 110:76-82.
60. Klopfleisch R, von Euler H, Sarli G, et al. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol 2011, 48:98-116.
61. Rivera P, von Euler H Molecular biological aspects on canine and human mammary tumors. Vet Pathol 2011, 48:132-146.
62. Gilbertson SR, Kurzman ID, Zachrau RE, et al. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983, 20:127-142.
63. Moulton JE, Rosenblatt LS, Goldman M Mammary tumors in a colony of beagle dogs. Vet Pathol 1986, 23:741-749.
64. Bender AP, Dorn CR, Schneider R An epidemiologic study of canine multiple primary neoplasma involving the female and male reproductive systems. Prev Vet Med 1984, 2:715-731.
65. Antuofermo E, Miller MA, Pirino S, et al. Spontaneous mammary intraepithelial lesions in dogs-a model of breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:2247-2256.
66. MacEwen EG, Patnaik AK, Harvey HJ, et al. Estrogen receptors in canine mammary tumors. Cancer Res 1982, 42:2255-2259.
67. Rutteman GR, Misdorp W, Blankenstein MA, et al. Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. Br J Cancer 1988, 58:594-599.
68. Illera JC, Perez-Alenza MD, Nieto A, et al. Steroids and receptors in canine mammary cancer. Steroids 2006, 71:541-548.
69. Millanta F, Calandrella M, Bari G, et al. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci 2005, 79:225-232.
70. Donnay I, Rauis J, Devleeschouwer N, et al. Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. Am J Vet Res 1995, 56:1188-1194.
71. de Las Mulas JM, Millan Y, Dios R A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol 2005, 42:200-212.
72. Chang CC, Tsai MH, Liao JW, et al. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc 2009, 235:391-396.
73. Nieto A, Pena L, Perez-Alenza MD, et al. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 2000, 37:239-247.
74. Geraldes M, Gartner F, Schmitt F Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours. Vet Rec 2000, 146:403-406.
75. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
76. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
77. Network NCC Clinical practice guidelines in oncology-version 2.2006 2005, National Comprehensive Cancer Network, Inc.
78. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
79. Thuerlimann B, Koeberle D, Senn HJ Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. Eur J Cancer 2007, 43:46-52.
80. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
81. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998, 16:462-469.
82. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
83. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
84. Martin de las Mulas J, Ordas J, Millan Y, et al. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 2003, 80:363-367.
85. Hsu WL, Huang HM, Liao JW, et al. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J 2009, 180:116-123.
86. Gama A, Alves A, Schmitt F Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 2008, 453:123-132.
87. Perez Alenza MD, Tabanera E, Pena L Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001, 219:1110-1114.
88. Marconato L, Romanelli G, Stefanello D, et al. Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008). J Am Vet Med Assoc 2009, 235:967-972.
89. Karayannopoulou M, Koutinas AF, Polizopoulou ZS, et al. Total serum alkaline phosphatase activity in dogs with mammary neoplasms: a prospective study on 79 natural cases. J Vet Med A Physiol Pathol Clin Med 2003, 50:501-505.
90. Karayannopoulou M, Polizopoulou ZS, Koutinas AF, et al. Serum alkaline phosphatase isoenzyme activities in canine malignant mammary neoplasms with and without osseous transformation. Vet Clin Pathol 2006, 35:287-290.
91. Cassali GD, Gobbi H, Malm C, et al. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: comparative features with human tumours. Cytopathology 2007, 18:191-196.
92. Simon D, Schoenrock D, Nolte I, et al. Cytologic examination of fine-needle aspirates from mammary gland tumors in the dog: diagnostic accuracy with comparison to histopathology and association with postoperative outcome. Vet Clin Pathol 2009, 38:521-528.
93. Eberle N, Fork M, von Babo V, et al. Comparison of examination of thoracic radiographs and thoracic computed tomography in dogs with appendicular osteosarcoma. Vet Comp Oncol 2011, 9:131-140.
94. Otoni CC, Rahal SC, Vulcano LC, et al. Survey radiography and computerized tomography imaging of the thorax in female dogs with mammary tumors. Acta Vet Scand 2010, 52:20.
95. Lana SE, Rutteman GR, Withrow SJ Tumors of the mammary gland. Withrow & MacEwen's small animal clinical oncology 2007, Saunders Elsevier, St. Louis. ed 4. S.J. Withrow, D.M. Vail (Eds.).
96. Pereira CT, Rahal SC, de Carvalho Balieiro JC, et al. Lymphatic drainage on healthy and neoplastic mammary glands in female dogs: can it really be altered?. Anat Histol Embryol 2003, 32:282-290.
97. Pereira CT, Luiz Navarro Marques F, Williams J, et al. 99mTc-labeled dextran for mammary lymphoscintigraphy in dogs. Vet Radiol Ultrasound 2008, 49:487-491.
98. Patsikas MN, Dessiris A The lymph drainage of the mammary glands in the bitch: a lymphographic study. Part II: The 3rd mammary gland. Anat Histol Embryol 1996, 25:139-143.
99. Ran S, Volk L, Hall K, et al. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2009, 17(4):229-251.
100. Tuohy JL, Milgram J, Worley DR, et al. A review of sentinel lymph node evaluation and the need for its incorporation into veterinary oncology. Vet Comp Oncol 2009, 7:81-91.
101. Owens L Classification of tumors in domestic animals 1980, World Health Organization, Geneva.
102. Rutteman G, Withrow S, MacEwen E Tumors of the mammary gland. Small animal clinical oncology 2001, WB Saunders, Philadelphia. ed 3. S. Withrow, E. MacEwen (Eds.).
103. Sorenmo KU, Rasotto R, Zappulli V, et al. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol 2011, 48:85-97.
104. Hampe JF, Misdorp W Tumours and dysplasias of the mammary gland. Bull World Health Organ 1974, 50:111-133.
105. Misdorp W, Else R, Hellmen E, et al. Histological classification of mammary tumors of the dog and the cat 1999, American Registry of Pathology, Washington, DC.
106. Goldschmidt M, Pena L, Rasotto R, et al. Classification and grading of canine mammary tumors. Vet Pathol 2011, 48:117-131.
107. Rasotto R, Zappulli V, Castagnaro M, et al. A retrospective study of those histopathologic parameters predictive of invasion of the lymphatic system by canine mammary carcinomas. Vet Pathol 2012, 49(2):330-340.
108. Elston CW, Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
109. Misdorp W Tumors of the mammary gland. Tumors in domestic animals 2002, Iowa State Press, Ames, Iowa. ed 4. D.J. Meuten (Ed.).
110. Clemente M, Perez-Alenza MD, Illera JC, et al. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet Pathol 2010, 47:265-274.
111. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, et al. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 2005, 133:246-252.
112. Hellmen E, Bergstrom R, Holmberg L, et al. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 1993, 30:20-27.
113. Perez Alenza MD, Pena L, Nieto AI, et al. Clinical and pathological prognostic factors in canine mammary tumors. Ann Ist Super Sanita 1997, 33:581-585.
114. MacEwen EG, Harvey HJ, Patnaik AK, et al. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol Response Mod 1985, 4:418-426.
115. Philibert JC, Snyder PW, Glickman N, et al. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med 2003, 17:102-106.
116. Morris JS, Dobson JM, Bostock DE Use of tamoxifen in the control of canine mammary neoplasia. Vet Rec 1993, 133:539-542.
117. Chang SC, Chang CC, Chang TJ, et al. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc 2005, 227:1625-1629.
118. Stratmann N, Failing K, Richter A, et al. Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg 2008, 37:82-86.
119. Morris JS, Dobson JM, Bostock DE, et al. Effect of ovariohysterectomy in bitches with mammary neoplasms. Vet Rec 1998, 142:656-658.
120. Sorenmo KU, Shofer FS, Goldschmidt MH Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med 2000, 14:266-270.
121. MacEwen EG Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136.
122. Vail DM, MacEwen EG Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000, 18:781-792.
123. Gelb HR, Freeman LJ, Rohleder JJ, et al. Feasibility of contrast-enhanced ultrasound-guided biopsy of sentinel lymph nodes in dogs. Vet Radiol Ultrasound 2010, 51:628-633.
124. Pinheiro LG, Oliveira Filho RS, Vasques PH, et al. Hemosiderin: a new marker for sentinel lymph node identification. Acta Cir Bras 2009, 24:432-436.
125. Balogh L, Thuroczy J, Andocs G, et al. Sentinel lymph node detection in canine oncological patients. Nucl Med Rev Cent East Eur 2002, 5:139-144.
126. Wong JH, Cagle LA, Morton DL Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991, 214:637-641.
127. Szczubiał M, Łopuszynski W Prognostic value of regional lymph node status in canine mammary carcinomas. Vet Comp Oncol 2011, 9:296-303.
128. Allen S, Mahaffey E Canine mammary neoplasia: prognostic indicators and response to surgical therapy. J Amer Anim Hosp Assoc 1989, 25:504-546.
129. Tavares WL, Lavalle GE, Figueiredo MS, et al. Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet Scand 2010, 52:67.
130. Yamagami T, Kobayashi T, Takahashi K, et al. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. J Small Anim Pract 1996, 37:462-464.
131. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, et al. Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med 2001, 48:85-96.
132. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999, 17:1413-1424.
133. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194-1201.
134. Morabito A, Piccirillo MC, Monaco K, et al. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist 2007, 12:1288-1298.
135. Simon D, Schoenrock D, Baumgartner W, et al. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006, 20:1184-1190.
136. Marconato L, Lorenzo RM, Abramo F, et al. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 2008, 6:90-101.
137. de MSCH, Toledo-Piza E, Amorin R, et al. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J 2009, 50:506-510.
138. Kuntz CA, Dernell WS, Powers BE, et al. Extraskeletal osteosarcomas in dogs: 14 cases. J Am Anim Hosp Assoc 1998, 34:26-30.
139. Hermo GA, Turic E, Angelico D, et al. Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade. J Am Anim Hosp Assoc 2011, 47:21-27.
140. Terraube V, Marx I, Denis CV Role of von Willebrand factor in tumor metastasis. Thromb Res 2007, 120(Suppl 2):S64-S70.
141. Ripoll GV, Giron S, Krzymuski MJ, et al. Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res 2008, 28:2607-2611.
142. Hahn K, Richardson R, Knapp D Canine malignant mammary neoplasia: biological behavior, diagnosis, and treatment alternatives. J Am Anim Hosp Assoc 1992, 28:251-256.
143. Egenvall A, Bonnett BN, Haggstrom J, et al. Morbidity of insured Swedish cats during 1999-2006 by age, breed, sex, and diagnosis. J Feline Med Surg 2010, 12:948-959.
144. Bonnett BN, Egenvall A Age patterns of disease and death in insured Swedish dogs, cats and horses. J Comp Pathol 2010, 142(Suppl 1):S33-S38.
145. Teclaw R, Mendlein J, Garbe P, et al. Characteristics of pet populations and households in the Purdue Comparative Oncology Program catchment area, 1988. J Am Vet Med Assoc 1992, 201:1725-1729.
146. Vascellari M, Baioni E, Ru G, et al. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res 2009, 5:39.
147. Hayden DW, Nielsen SW Feline mammary tumours. J Small Anim Pract 1971, 12:687-698.
148. Misdorp W, Romijn A, Hart AA Feline mammary tumors: a case-control study of hormonal factors. Anticancer Res 1991, 11:1793-1797.
149. Hayes AA, Mooney S Feline mammary tumors. Vet Clin North Am Small Anim Pract 1985, 15:513-520.
150. Weijer K, Head KW, Misdorp W, et al. Feline malignant mammary tumors. I. Morphology and biology: some comparisons with human and canine mammary carcinomas. J Natl Cancer Inst 1972, 49:1697-1704.
151. Hayes HM, Milne KL, Mandell CP Epidemiological features of feline mammary carcinoma. Vet Rec 1981, 108:476-479.
152. Ito T, Kadosawa T, Mochizuki M, et al. Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci 1996, 58:723-726.
153. Patnaik AK, Liu SK, Hurvitz AI, et al. Nonhematopoietic neoplasms in cats. J Natl Cancer Inst 1975, 54:855-860.
154. Rissetto K, Villamil JA, Selting KA, et al. Recent trends in feline intestinal neoplasia: an epidemiologic study of 1,129 cases in the veterinary medical database from 1964 to 2004. J Am Anim Hosp Assoc 2011, 47:28-36.
155. Louwerens M, London CA, Pedersen NC, et al. Feline lymphoma in the post-feline leukemia virus era. J Vet Intern Med 2005, 19:329-335.
156. Gabor LJ, Malik R, Canfield PJ Clinical and anatomical features of lymphosarcoma in 118 cats. Aust Vet J 1998, 76:725-732.
157. Miller MA, Nelson SL, Turk JR, et al. Cutaneous neoplasia in 340 cats. Vet Pathol 1991, 28:389-395.
158. Overley B, Shofer FS, Goldschmidt MH, et al. Association between ovarihysterectomy and feline mammary carcinoma. J Vet Intern Med 2005, 19:560-563.
159. Skorupski KA, Overley B, Shofer FS, et al. Clinical characteristics of mammary carcinoma in male cats. J Vet Intern Med 2005, 19:52-55.
160. Jacobs TM, Hoppe BR, Poehlmann CE, et al. Mammary adenocarcinomas in three male cats exposed to medroxyprogesterone acetate (1990-2006). J Feline Med Surg 2010, 12:169-174.
161. Loretti AP, Ilha MR, Ordas J, et al. Clinical, pathological and immunohistochemical study of feline mammary fibroepithelial hyperplasia following a single injection of depot medroxyprogesterone acetate. J Feline Med Surg 2005, 7:43-52.
162. Mol JA, van Garderen E, Rutteman GR, et al. New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996, 57:67-71.
163. Mol JA, van Garderen E, Selman PJ, et al. Growth hormone mRNA in mammary gland tumors of dogs and cats. J Clin Invest 1995, 95:2028-2034.
164. Burrai GP, Mohammed SI, Miller MA, et al. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156.
165. Millanta F, Calandrella M, Vannozzi I, et al. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec 2006, 158:821-824.
166. de las Mulas JM, van Niel M, Millan Y, et al. Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domest Anim Endocrinol 2000, 18:111-125.
167. Martin de las Mulas J, Van Niel M, Millan Y, et al. Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci 2002, 72:153-161.
168. Meisl D, Hubler M, Arnold S [Treatment of fibroepithelial hyperplasia (FEH) of the mammary gland in the cat with the progesterone antagonist Aglepristone (Alizine)]. Schweiz Arch Tierheilkd 2003, 145:130-136.
169. Ordas J, Millan Y, Dios R, et al. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179.
170. Millanta F, Calandrella M, Citi S, et al. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005, 42:30-34.
171. Winston J, Craft DM, Scase TJ, et al. Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 2005, 3:8-15.
172. Rasotto R, Caliari D, Castagnaro M, et al. An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 2011, 144:170-179.
173. Brodey RS Canine and feline neoplasms. Adv Vet Sci 1957, 24:434.
174. Weijer K, Hart AA Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983, 70:709-716.
175. Perez-Alenza MD, Jimenez A, Nieto AI, et al. First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases. Breast Cancer Res 2004, 6:R300-R307.
176. McNeill CJ, Sorenmo KU, Shofer FS, et al. Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma. J Vet Intern Med 2009, 23:123-129.
177. Hayden DW, Barnes DM, Johnson KH Morphologic changes in the mammary gland of megestrol acetate-treated and untreated cats: a retrospective study. Vet Pathol 1989, 26:104-113.
178. Castagnaro M, Casalone C, Bozzetta E, et al. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol 1998, 119:263-275.
179. Seixas F, Palmeira C, Pires MA, et al. Mammary invasive micropapillary carcinoma in cats: clinicopathologic features and nuclear DNA content. Vet Pathol 2007, 44:842-848.
180. Seixas F, Pires MA, Lopes CA Complex carcinomas of the mammary gland in cats: pathological and immunohistochemical features. Vet J 2008, 176:210-215.
181. Sarli G, Brunetti B, Benazzi C Mammary mucinous carcinoma in the cat. Vet Pathol 2006, 43:667-673.
182. Kamstock DA, Fredrickson R, Ehrhart EJ Lipid-rich carcinoma of the mammary gland in a cat. Vet Pathol 2005, 42:360-362.
183. Matsuda K, Kobayashi S, Yamashita M, et al. Tubulopapillary carcinoma with spindle cell metaplasia of the mammary gland in a cat. J Vet Med Sci 2008, 70:479-481.
184. Seixas F, Palmeira C, Pires MA, et al. Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis. Vet J 2011, 187:65-71.
185. MacEwen EG, Hayes AA, Mooney S, et al. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response Mod 1984, 3:541-546.
186. Viste JR, Myers SL, Singh B, et al. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. Can Vet J 2002, 43:33-37.
187. MacEwen EG, Hayes AA, Harvey HJ, et al. Prognostic factors for feline mammary tumors. J Am Vet Med Assoc 1984, 185:201-204.
188. Borrego JF, Cartagena JC, Engel J Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*. Vet Comp Oncol 2009, 7:213-221.
189. Patsikas MN, Papadopoulou PL, Charitanti A, et al. Computed tomography and radiographic indirect lymphography for visualization of mammary lymphatic vessels and the sentinel lymph node in normal cats. Vet Radiol Ultrasound 2010, 51:299-304.
190. Jeglum KA, deGuzman E, Young KM Chemotherapy of advanced mammary adenocarcinoma in 14 cats. J Am Vet Med Assoc 1985, 187:157-160.
191. Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988, 2:60-65.